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Myotonic dystrophy type 1 (DM1, MIM #160900), the most common muscular dystrophy
among adults, is a multisystem disorder, which affects, besides the skeletal muscle,
several other tissues and/or organs, including the gastrointestinal apparatus, with
manifestations that frequently affect the quality of life of DM1 patients. So far, only few,
mainly retrospective studies evaluated this specific topic in DM1, so we performed a
perspective study, enrolling 61 DM1 patients who underwent an extensive diagnostic
protocol, including administration of the Gastrointestinal Symptom Rating Scale (GSRS),
a validated patient-reported questionnaire about GI symptoms, laboratory tests, liver
US scan, and an intestinal permeability assay, in order to characterize frequency and
assess correlations regarding specific gastrointestinal manifestations with demographic
or other DM1-related features. Our results in our DM1 cohort confirm the high frequency
of various gastrointestinal manifestations, with the most frequent being constipation
(45.9%). γGT levels were pathologically increased in 65% of DM1 patients and GPT
in 29.82%; liver ultrasound studies showed steatosis in 34.4% of patients. Significantly,
91.22% of DM1 patients showed signs of altered intestinal permeability at the specific
assay. We documented a gender-related prevalence and severity of gastrointestinal
manifestations in DM1 females compared to DM1 males, while males showed higher
serum GPT and γGT levels than females. Correlation studies documented a direct
correlation between severity of muscle weakness estimated by MIRS score and γGT
and alkaline phosphatase levels, suggesting their potential use as biomarkers of muscle
disease severity in DM1.
Keywords: myotonic dystrophy type 1, gastrointestinal symptoms, multisystem involvement, gender-related
differences, gastrointestinal symptom rating scale, intestinal permeability
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INTRODUCTION
Myotonic dystrophy type 1 or Steinert’s disease (DM1, MIM
#160900) is the most common form of adult-onset muscular
dystrophy, with an estimated prevalence of about 1:8000 among
Caucasians; recently, an epidemiological study conducted in the
Rome province estimated a total age-standardized prevalence of
9.65/100,000 for DM1 (1).
DM1 is an autosomal dominant, multisystem disorder,
caused by the pathologic expansion of a polymorphic CTG
triplet repeat in the 3′ non-coding region of DMPK gene
on chromosome 19q13.3, which encodes for the DM protein
kinase (MIM#605377). DMPK alleles from healthy subjects
contain 5–35 CTG repeats, while DM1 patients carry alleles
with expanded repeats ranging from 50 to more than 1,000
CTG repeats. The expanded DMPK allele shows both mitotic
and intergenerational instability biased toward expansion, which
explain the inter-individual variability due to tissue mosaicism
and the phenomenon of anticipation during linear transmission,
respectively (2). Many studies have shown that the length of
the CTG expansion in peripheral leukocytes inversely correlates
with the age of onset and directly with the severity of muscle
weakness (3, 4).
The pathogenesis of DM1 is complex, with a pivotal role
played by the toxic effect of the mutant DMPK pre-mRNAs
containing the expanded CUG stretch, which would eventually
disrupt the expression of other genes in various tissues by
impairing the function of specific transcription factors regulating
alternative splicing. As the DMPK mRNA is widely expressed in
many tissues, this explains the variable multisystem involvement
in DM1 patients, also affecting the central nervous system,
the eye, the heart, the smooth muscle, and the endocrine
system, with the related development of cognitive and behavioral
deficits, premature cataracts, cardiac conduction abnormalities,
endocrine dysfunctions, and gastrointestinal (GI) symptoms.
Regarding GI manifestations, these can be referred even by
children or adolescents affected by DM1; the most common
disturbances related to involvement of upper gastrointestinal
tract include dysphagia, heartburn, emesis, dyspepsia, vomiting,
coughing while eating, and regurgitation, whereas abdominal
pain, bloating, constipation, changes in bowel habits, diarrhea,
pseudo-obstruction, and dyschezia are the most common
complaints related to the lower digestive tract (5, 6). A moderate
increase of serum gamma GT levels is also found in most DM1
patients, and liver echo scan often shows signs of liver steatosis
and/or gallbladder stones (7, 8).
So far, only few studies have specifically assessed GI features
in DM1 patients, mainly based on a retrospective analysis of
collected data (9, 10) or only by questionnaires (5, 11).
Abbreviations: DM1: myotonic dystrophy type 1; GI: gastrointestinal;
OPES: oropharyngoesophageal scintigraphy; BMI: body mass index; MIRS:
Muscular Impairment Rating Scale; GPT: glutamate pyruvate transaminase;
ALT: alanine aminotransferase; γGT: gamma glutamyl transferase; ESR:
erythrocyte sedimentation rate; US: ultrasound; 51Cr-EDTA: chromium-51-
labeled ethylenediamine tetraacetic acid; GSRS: Gastrointestinal Symptom Rating
Scale; GERD: gastroesophageal reflux disease; NAFLD: non-alcoholic fatty liver
disease; PPI: proton pump inhibitors.
These considerations prompted us to perform a perspective
study to assess in detail the spectrum of specific gastrointestinal
features in a cohort of 61 patients with molecular diagnosis
of DM1, in order to estimate the prevalence of individual GI
manifestations and analyze their correlation with demographic
(i.e., gender, age) or DM1-specific features (i.e., age at onset
of muscle symptoms, severity of muscle phenotype, nCTG
in leukocytes).
MATERIALS AND METHODS
The study design was made according to the Declaration
of Helsinki and approved by the Ethical Committee of our
Institution (Prot. 28458/19 ID: 2665). All patients gave their
written informed consent to partecipate to the study.
Patients
The study cohort includes 61 adult DM1 patients (57.4% males,
mean age at examination 47.20 ± 13.85 years) consecutively
enrolled from January to November 2019 at the Department of
Neurology of our Institution; eight of them, diagnosed and in
follw-up at the S. Camillo Forlanini Hospital were referred by
their neurologist (dr A. Petrucci) to our Center for the study
enrollment and the instrumental diagnostic protocol. Inclusion
criteria were as follows: age >18 years, molecular diagnosis of
DM1with estimation of the nCTG size in leukocytes, and capacity
to give informed consent to participate to this study and to the
collection of their demographic and diagnostic data for clinical
research purposes. All enrolled patients, except one positive to
hepatitis C antibodies determination, were negative to hepatitis
B and C and to celiac disease serologic testing.
Collected data for the study included the following:
- demographic data (gender, age);
- age at DM1 symptoms onset;
- DM1 disease duration (in years);
- Muscular Impairment Rating Scale (MIRS) (12) score assessed
at the time of study enrolment;
- mean (CTG)n value detected in leukocytes at diagnosis;
- body mass index (BMI) assessed by weight [kg]/height [m]2:
BMI <18.49 kg/m2 = underweight; 18.5–24.99 kg/m2 =
normal weight; 25–29.99 kg/m2 = overweight; >30 kg/m2
= obesity;
- presence of comorbidities, such as hypertension, liver
steatosis, diabetes type II;
- current medical therapies.
The GI diagnostic assessment included the following:
- administration of a validated self-reported questionnaire:
presence and severity of GI symptoms were assessed by a
limited version of the Gastrointestinal Symptom Rating Scale
(GSRS) simplified in order to increase the compliance of DM1
patients, and concerning only five main symptom clusters
(gastroesophageal reflux disease—GERD—item 3, abdominal
discomfort—item 1, abdominal pain—item 4, constipation—
item 10, and diarrhea—item 11 questionnaire (13, 14);
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- laboratory tests, including serum fasting glucose (normal
values < 110 mg/dl), glutamate pyruvate transaminase
(GPT)/alanine aminotransferase (ALT) (normal values < 45
UI/L), gamma glutamyl transferase (γGT) (normal values <
36 UI/L), alkaline phosphatase (normal values < 104 UI/L),
amylase (normal values < 106 UI/L), creatinine (normal
values 0.67–1.17mg/dl), total cholesterol (normal values <
200 mg/dl), triglycerides (normal values < 170 mg/dl),
vitamin D levels (normal values 31–100 ng/mL), erythrocyte
sedimentation rate (ESR) (normal values < 30 mm/h);
- liver ultrasound (US) scan: this test was performed after at least
6 h fasting with the patient in the supine decubitus position
and the right arm in maximal abduction; the probe was placed
in the right intercostal space that provides the best view of the
right liver lobe. A B-mode scanning was performed to assess
the presence and degree of liver steatosis and to select the most
appropriate area of the right lobe (at least 5 cm in diameter)
free of large vessels, and 2 cm below the liver capsule;
- intestinal permeability assay: for this test, after an overnight
fast, patients were given to drink 0.37 MBq of 51Cr-
EDTA (chromium-51 labeled ethylenediamine tetraacetic
acid) (Amersham Health, England) in 10ml of water. A
sample corresponding to 1/50 of the total amount (0.1ml) was
collected and used as the standard sample. After drinking the
parafarmaceutical, patients were asked to collect their 24-hour
urine. Then a 3ml patient’s sample from the urine collection
and the reference standard sample were both measured by
gamma counter (LKB-Wallac 1282 Compugamma, Turku,
Finland). To assess urinary excretion of 51Cr-EDTA, that
was calculated using the following formula: (Mean Urinary
Counts × Urinary Volume) × (Standard counts × 50)−1; the
result was expressed as percentage of administered dose and
considered indicative of altered intestinal permeability when
the calculated percentage value was >3% (15, 16). 51Cr-EDTA
is normally used for the evaluation of the glomerular filtration
rate after an intravenous injection, in view of its glomerular
extraction fraction of 1.0 ml/min/1.73 m2 and renal excretion
time of 5min. According to its high molecular weight, if
administered orally, the intestinal 51Cr-EDTA absorption is
minimal in healthy subjects (about 1–3%). On the contrary,
in cases of increased transmural permeability due to any
damage of the intestinal barrier, the amount of 51Cr-EDTA
passing into the bloodstream increases proportionally with the
extent and severity of the damage, followed by a rapid renal
clearance (17).
Statistical Analysis
Statistical analysis of data was performed by SPSS (Statistical
Package for Social Science) version 24.0 to obtain descriptive
statistics concerning demographic, clinical, molecular, and
diagnostic data. To assess the presence of any associations
between specific GI or other DM1 features with gender, we
used the Mann–Whitney U test and the Fisher’s two-tailed exact
test to compare numerical and nominal variables between the
two groups, respectively. In addition, Spearman correlation test
was performed between numerical variables in pairs, to assess
the presence of correlations between either (CTG)n, MIRS or
BMI score with other numerical variables assessed in the cohort,
including demographic characteristics (age at examination, age at
onset, disease duration in years), serum laboratory tests (fasting
glucose, GPT, GGT, alkaline phosphatase, amylase, creatinine,
cholesterol, triglycerides, vitamin D, and ESR), and diagnostic
tests (total IP expressed as % values) (Supplementary Table 1).
RESULTS
Overall (Table 1), our cohort included 35 male and 26 female
adult DM1 patients. Mean age at onset was 32.34 ± 15.28 years,
with a mean duration of disease of 14.85 ± 9.37 years. Mean
MIRS score was 2.89 ± 0.84 (range 2–5), and (CTG)n size was
466.17± 269.32 (range 78–1200).
Administration of the GSRS questionnaire documented that
72% of DM1 patients referred at least one GI symptom: the
most common was constipation (45.9%), followed by abdominal
discomfort (44.3%), GERD (39.3%), diarrhea (39.3%), abdominal
pain (32.8%), and alternating constipation/diarrhea (24.6%).
GSRS scores, indicating the severity of GI symptoms, were the
highest for constipation (2.47 ± 1.83), followed by abdominal
discomfort (2.31 ± 1.80), GERD (2.16 ± 1.69), abdominal pain
(1.95± 1.62), and diarrhea (1.89± 1.38).
Regarding laboratory tests, γGT levels were pathologically
increased (mean value 88.22 ± 101.71 UI/L) in 65% of DM1
patients, alkaline phosphatase (mean 80.81 ± 31.66 UI/L) in
19.7% of DM1 patients, and GPT in 29.82% of the patients;
amylase was out of normal range in only 3 patients. Mean
value for triglycerides was 152.41 ± 71.14 mg/dl; elevated total
cholesterol (mean 187.39 ± 40.62 mg/dl) was found in 35.59%
of patients.
Liver US showed steatosis in 34.4% of patients, and 31.1%
of patients had cholelithiasis. Overall, 19.7% had undergone
cholecystectomy for gallbladder stones. Only 8.2% of all DM1
patients took ursodeoxycholic acid. The DM1 patient positive for
hepatitis C virus did not show any structural liver involvement at
US studies.
Of note, most of our DM1 patients (91.22%) showed signs of
altered intestinal permeability at the IP test.
Regarding comorbidities, 18% of patients suffered from
hypertension, controlled by anti-hypertensive drugs in all of
them. About 13% of our DM1 cohort was frankly obese (BMI
> 30). 9.8% of patients suffered from type II diabetes, while
reduced vitamin D was detected in about two thirds of patients.
Regarding pharmacological treatment of GI symptoms,
34.4% of patients took proton pump inhibitors (PPI); 11.5%,
anti-constipation medicines; and 6.6%, long-term probiotics.
Moreover, 23% of them assumed hypolipidemic drugs (either
ezetimibe or omega 3-fatty acids), about 50% of patients took
vitaminD oral supplements, 8.2% patients were in treatment with
metformin, and 4.9% also required subcutaneous insulin.
Statistical analysis (Table 2) documented significant gender-
related differences regarding frequency of GI complains:
DM1 females (88.5%) referred at least one GI symptom more
frequently compared to DM1 males (60%), with constipation
being their main complain (65.4 vs. 31.4%), followed by
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TABLE 1 | Demographic, molecular and clinical characteristics of the cohort of
study.
Count (%) Mean (SD) n
Male 35 (57.4%) 61
Age at disease onset 32.34 (15.28) 61
Age at examination 47.20 (13.85) 61
Disease duration 14.85 (9.37) 61
BMI 24.21 (4.78) 61








Diabetes type II 6 (9.8%)
Cholelithiasis 19 (31.1%)
Cholecistectomy 12 (19.7%)
Hepatitis C 1 (1.6%)
GI symptoms 44 (72%) 61
GERD 24 (39.3%)
GERD (GSRS score) 2.16 (1.69)































Vitamine D supplements 30 (49.2%)
Blood tests




GPT 38.46 (24.77) 57







TABLE 1 | Continued
Count (%) Mean (SD) n
GGT out of range (>36
UI/l)
39 (65%) 60
Alkaline phosphatase 80.81 (31.66) 54










Vitamine D 24.75 (13.05) 48
Vitamine D below the
normal range (<30 UI/l)
32 (66.67%) 48





Total IP 6.71 (4.57) 57
Altered 52 (91.22%) 57
SD, standard deviation; BMI, Body Mass Index; MIRS, muscular impairment rating scale;
GI, gastrointestinal; GERD, gastroesophageal reflux disease; GSRS, Gastrointestinal
Symptom Rating Scale; NAFLD, non-alcoholic fatty liver disease; PPI, proton pump
inhibitor; IP, intestinal permeability.
abdominal discomfort (61.5 vs. 31.4%), and alternating
constipation/diarrhea (38.5 vs. 14.3%). Also, the severity of GI
symptoms by GSRS score was more severe in DM1 females than
males: constipation (3.04 ± 1.82 vs. 2.06 ± 1.75) resulted the
most severe, followed by abdominal discomfort (2.85 ± 1.80
vs. 1.91 ± 1.72), and abdominal pain (2.53 ± 1.90 vs. 1.51 ±
1.22). On the other hand, GERD and diarrhea resulted in having
similar frequency and are mild in both DM1 groups.
Conversely, serumGPT (43.94± 26.45 vs. 30.92± 20.46UI/L)
and γGT (103.23 ± 89.71 vs. 67.20 ± 115.08 UI/L) levels were
both significantly higher in DM1 males vs. females, and γGT
also resulted in being more frequently pathologically increased
(80 vs. 44%). Finally, creatinine serum levels were normal in all
patients, being also higher in males (0.84 vs. 0.63 mg/dl).
Correlation analysis by Spearman’s test
(Supplementary Table 1) showed that:
- (CTG)n inversely correlated only with age at onset of disease
(r =−0.326; p= 0.017);
- MIRS score directly correlated with age at the examination
(r = 0.401; p= 0.001), disease duration (r = 0.473; p≤ 0.001),
GGT (r = 0.390; p = 0.002), and alkaline phosphatase levels
(r = 0.362; p= 0.007);
- BMI directly correlated with disease duration (r = 0.364;
p = 0.004), GPT (r = 0.356; p = 0.007), and γGT levels
(r = 0.316; p= 0.014).
DISCUSSION
The aim of this study was to assess in detail the
prevalence and the characteristics of GI involvement
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TABLE 2 | Statistical analysis for gender-related issues.
Male = 35 (57.38%) Female = 26 (42.62%) FET MWUT
Count (%) Mean (SD) n Count (%) Mean (SD) n
Age at disease onset 30.54 (13.92) 35 34.77 (16.91) 26 NS
Age at examination 47.03 (11.50) 35 47.42 (16.74) 26 NS
Disease duration 16.49 (9.22) 35 12.65 (9.29) 26 NS
BMI 24.94 (5.01) 35 23.23 (4.35) 26 NS
BMI≥30 6 (17.1%) 35 2 (7.7%) 26 NS
(CTG)n 427.87 (260.17) 31 506.05 (282.94) 22 NS
MIRS score 2.94 (0.80) 35 2.81 (0.90) 26 NS
Comorbidities
Hypertension 6 (17.1%) 5 (19.2%) NS
Steatosis 14 (40.0%) 35 7 (26.9%) 26 NS
Diabetes type II 5 (14.3%) 35 1 (3.8%) 26 NS
Cholelithiasis 9 (25.7%) 35 10 (38.5%) 26 NS
Cholecistectomy 7 (20.0%) 35 5 (19.2%) 26 NS
Hepatitis C 0 (0%) 35 1 (3.8%) 26 NS
≥1 GI symptoms 21 (60.0%) 35 23 (88.5%) 26 0.020
GERD 14 (40%) 35 10 (38.5%) 26 NS
GERD (GSRS score) 2.20 (1.71) 2.12 (1.70) NS
Abdominal discomfort 11 (31.4%) 35 16 (61.5%) 26 0.036
Abdominal discomfort (GSRS score) 1.91 (1.72) 2.85 (1.80) 0.017
Abdominal pain 8 (22.9%) 35 12 (46.2%) 26 NS
Abdominal pain (GSRS score) 1.51 (1.22) 2.53 (1.90) 0.021
Constipation 11 (31.4%) 35 17 (65.4%) 26 0.011
Constipation (GSRS score) 2.06 (1.75) 3.04 (1.82) 0.020
Diarrhea 11 (31.4%) 35 13 (50%) 26 NS
Diarrhea (GSRS score) 1.69 (1.16) 2.15 (1.62) NS
Alternating constipation/diarrhea 5 (14.3%) 1.69 (1.16) 35 10 (38.5%) 26 0.039
Medications
Mexiletine 9 (25.7%) 35 5 (19.2%) 26 NS
Anti-hypertensives 6 (17.1%) 35 5 (19.2%) 26 NS
Aspirin 6 (17.1%) 35 5 (19.2%) 26 NS
Insulin 2 (5.7%) 35 1 (3.8%) 26 NS
Metformin 2 (5.7%) 35 3 (11.5%) 26 NS
Ursodeoxycholic acid 5 (14.3%) 35 0 (0%) 26 NS
Hypolipidemic drugs 9 (25.7%) 35 5 (19.2%) 26 NS
Anti-constipation medicines 4 (11.4%) 35 3 (11.5 %) 26 NS
PPIs 13 (37.1%) 35 8 (30.8%) 26 NS
Probiotics 3 (8.6%) 35 1 (3.8%) 26 NS
Vitamine D supplements 19 (54.3%) 35 11 (42.3%) 26 NS
Blood tests
Glucose 92.57 (29.82) 35 90.77 (22.34) 26 NS
Glucose out of range (>110 UI/l)
GPT 43.94 (26.45) 33 30.92 (20.46) 24 0.006
GPT out of range (>45 UI/l) 13 (60.6%) 33 4 (16.7%) 24 NS
GGT 103.23 (89.71) 35 67.20 (115.08) 25 0.002
GGT out of range (>36 UI/l) 28 (80%) 35 11 (44%) 25 0.006
Alkaline phosphatase 76.70 (26.60) 33 87.29 (38.11) 21 NS
Amylase 60.71 (34.41) 28 54.94 (21.22) 17 NS
Total cholesterol 186.20 (43.23) 35 191.17 (37.19) 24 NS
Triglycerides 161.31 (76.66) 35 139.42 (61.48) 24 NS
Vitamine D 24.65 (12.28) 28 24.89 (14.39) 20 NS
(Continued)
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TABLE 2 | Continued
Male = 35 (57.38%) Female = 26 (42.62%) FET MWUT
Count (%) Mean (SD) n Count (%) Mean (SD) n
Vitamine D below the normal range (<30 UI/l) 19 (67.9%) 28 13 (65.0%) 20 NS
Creatinine 0.84 (0.25) 34 0.63 (0.19) 25 0.001
Erythrocyte Sedimentation Rate 10.62 (10.77) 26 19.30 (22.67) 20 NS
Intestinal permeability (IP)
Total IP 6.94 (5.02) 33 6.40 (3.97) 24 NS
Altered 31 (93.9%) 33 21 (87.5%) 24 NS
SD, standard deviation; BMI, Body Mass Index; MIRS, muscular impairment rating scale; GI, gastrointestinal; GERD, gastroesophageal reflux disease; GSRS, Gastrointestinal Symptom
Rating Scale; NAFLD, non-alcoholic fatty liver disease; PPI, proton pump inhibitor; IP, intestinal permeability; FET, Fishers’ exact test; MWUT, Mann-Whitney U Test. Bold indicates
statistical significance of values.
in DM1 patients. To accomplish this, we performed a
perspective study on a significant cohort of DM1 patients
characterized about the occurrence of gastrointestinal
involvement by an extensive diagnostic panel: this included
subjective evaluation of the prevalence and severity
of GI manifestation by administering a validated GI
questionnaire, GSRS (13, 14), and objective assessment of
GI manifestations by blood and instrumental tests, including
US liver and a radionuclide-based assay for the intestinal
permeability (15).
The results of our study confirm a very high prevalence of
GI manifestations in DM1: indeed, 44/61 of our patients (72.1%)
referred at least one GI symptom, including constipation (45.9%),
referred GERD, and diarrhea (39.3%).
The prevalence of GI symptoms in our study is higher
than that reported by Hilbert et al. (5), who assessed the
prevalence of GI manifestations in a very large cohort of DM1
patients based on data obtained from the National Registry
of Myotonic Dystrophy; indeed, in that study, 38% of DM1
patients referred GERD, 33% constipation, and only 1.3%
diarrhea. However, our perspective study assessed the presence
of GI symptoms using one questionnaire, GSRS, specifically
validated, and certainly more sensitive to detect the presence
of GI symptoms (16–19). Given the need of validated outcome
measures to assess various systemic manifestations of DM1,
we are planning to validate specifically for DM1 this limited
version of Gastrointestinal Symptoms Rating Scale (GSRS),
concerning the domains depicting constipation, diarrhea,
abdominal pain, abdominal discomfort, GERD, as it resulted
in an easy, quick, and sensitive instrument for the assessment
of GI symptoms in DM1 patients. By this diagnostic tool, a
significant percentage of our DM1 patients reported various GI
symptoms, including abdominal discomfort (44.3%), abdominal
pain (32.8%), and/or alternating constipation/diarrhea (24.6%).
By using GSRS, we were also able to score the severity of
GI symptoms, which showed higher values for constipation
(2.47 ± 1.83), followed by abdominal discomfort (2.31 ±
1.80), GERD (2.16 ± 1.69), abdominal pain (1.95 ± 1.62), and
diarrhea (1.89± 1.38).
Regarding diagnostic tests, confirming our previous
observations (20), liver US documented a significant prevalence
of steatosis (34.4%), and gallbladder stones (total 31.1%). The
significant prevalence of such manifestations in DM1 is also
highlighted by another study conducted on 31 DM1 patients (21)
documenting the presence of liver steatosis with abnormal liver
tests in 54% of cases.
Most strikingly, the majority of our DM1 patients (91.22%)
showed an altered intestinal permeability. We performed the
intestinal permeability test in DM1 patients, since a previous
study (22) had shown that non-alcoholic fatty liver disease
(NAFLD) was significantly associated with an increased gut
permeability caused by disruption of intercellular tight junctions,
which could therefore play an important role in the pathogenesis
of hepatic fat deposition.
Although an abnormal IP occurred virtually in all our DM1
patients, liver US scan documented steatosis only in 34.4% of
them, and these data might suggest that an increased IP might
represent a very early GI manifestation in DM1, preceding the
occurrence of liver steatosis.
Determinants of fatty liver degeneration in DM1 are not yet
clarified, and so far, only one study (7) analyzing a cohort of
36 DM1 patients, documented a high prevalence of NAFLD
(about 38% of patients) and its strong association with markers
of insulin resistance and features of the metabolic syndrome.
NAFLD is strongly associated with insulin resistance and type
2 diabetes (23), which in turn are associated with DM1 (24),
being likely related to the aberrant expression of the insulin
receptor documented in DM1 peripheral tissues (25–27). To
clarify this issue, we are going to evaluate in a further study
prevalence and predictors of NAFLD in our cohort of DM1
patients, in comparison to a non-DM1-NAFLD cohort. NAFLD
is strongly associated with insulin resistance and type 2 diabetes
(23): both these conditions are frequent features also in DM1
(24), being likely related to the aberrant expression of the
insulin receptor in the peripheral tissues (25–27) and/or to
the presence of other post-receptor signaling abnormalities in
DM1 tissues (28).
It is recognized that an impaired motility of the GI smooth
muscle, either caused by primary myofiber dysfunction or
secondary to neural damage (11, 29), and with a possible
concomitant contribution from endocrine dysfunctions (29),
underlies the various GI disturbances affecting DM1 patients.
In this regard, the altered intestinal permeability documented
in most of our DM1 patients might be consequent to the gut
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dysmotility, which could eventually cause a bacterial overgrowth
(30) responsible for diarrhea or alternating alvus, while a delayed
and reduced gallbladder contraction consequent to the toxic
RNA effect occurring in its tissues (8) might predispose to
gallstone formation.
Moreover, contractions of bile canaliculi and bile ductules
(29) could be responsible for the elevation of γGT detected in
DM1 patients (10, 31–33), that we confirmed also in our DM1
cohort (65% of cases). Also, our laboratory findings confirmed,
in agreement with previous studies (29, 33–35), increased levels
of serum alkaline phosphatase, GPT, triglycerides, and total
cholesterol values in a significant percentage of DM1 patients
(Table 1), although with some differences in the individual
prevalence of such alterations possibly depend on different
dietary habits.
Also, the prevalence of comorbidities such as hypertension,
type 2 diabetes, and obesity was similar in our cohort to those
reported by other studies (35).
In agreement with previous studies (5, 9, 10), our study
confirms the presence of significant gender-related differences
regarding frequency and severity of GI manifestations in
DM1 (Table 2), with female patients showing a higher
prevalence of GI symptoms, and males showing higher
serum GPT and γGT levels. Such differences might be
related to several factors, including hormonal status or sex
differences in the gut microbiota composition (36), which of
course deserve further studies. On the other hand, we did
not find any gender-related differences for other metabolic
parameters (Table 2).
This study also confirmed the high frequency of low serum
vitamin D levels in DM1 patients originally described by
Terracciano et al. (37) in this regard, the frequent intestinal
permeability alterations in our cohort of DM1 patients might be
the cause for an intestinal malabsorption of vitamin D, although
another study suggests that in DM1 patients, low vitamin D levels
could be due to reduced sun exposure due to gait impairment or
to low intake of nutrients (38).
Besides the known correlations between nCTG and age
at onset or MIRS and age or disease duration, statistical
analysis interestingly documented a direct correlation between
severity of muscle weakness estimated by MIRS score, γGT,
and alkaline phosphatase levels, and these results would suggest
that both these indexes might be considered if this correlation
would be confirmed in a larger number of DM1 patients,
as potential disease biomarkers in DM1 in view of future
therapeutic trials.
Moreover, the correlation between BMI and γGT levels would
support the pathogenic contribution of insulin resistance in the
etiology of NAFLD in DM1.
The main limitation of this study concerns the relatively small
study cohort, including 61 DM1 patients; nevertheless, their
deep and homogeneous diagnostic characterization, particulrly
considering that DM1 is a rare disease, represent, to our opinion,
a strenght of this work. Another limitation consists in the the
lack of diagnostic tests assessing the upper GI tract involvement;
however, we previously documented via a retrospective analysis
on 70 DM1 patients a high frequency of upper GI dysfunction
tract by means of oropharyngoesophageal scintigraphy (OPES),
which, in our experience, becomes an appropriate diagnostic test
to assess and follow-up swallowing function in DM1 patients
(20). Also, we did not assess in such cohort the presence
of common lifestyle habits (smoke, alcohol intake) that may
influence the presence of GI symptoms or liver steatosis yet we
did not document a significant prevalence of such habits in a
previous study cohort concerning cancer risk in DM1 (39).
In conclusion, we documented a high prevalence, with
individual specific gender-related differences, of gastrointestinal
manifestations in DM1. Thus, the gender of DM1 patients should
be considered in the design of both medical management and
clinical trials.
Further studies are certainly needed to fully clarify the
complex pathophysiology of the gastrointestinal involvement in
DM1, in order to define specific guidelines regarding diagnostic
assessment and treatment of the various gastrointestinal
disturbances in DM1 patients, as they often affect the quality of
life of DM1 patients.
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